With Serial Entrepreneur At Its Helm, Arrakis Raises $38m To Target RNA With Small Molecules

Serial entrepreneur Michael Gilman has taken the helm of another start-up; after selling Padlock to Bristol-Myers and Stromedix to Biogen, his new company Arrakis has raised a $38m Series A round with big biopharma backing.